STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump closed the final of 17 drug‑pricing deals that the White House pursued last year.
- Regeneron will lower Medicaid drug prices, sell Praluent on TrumpRx for $225, and commit $27 billion to U.S. drug development.
- Otarmeni became the first gene therapy approved under the FDA’s National Priority Voucher program, and Regeneron will provide it at no cost to American patients.
- FDA granted the National Priority Voucher approval for Otarmeni, marking a new pathway for fast‑track gene‑therapy approvals.
- White House initially sought the 17 deals to curb prescription‑drug costs, now seeing the last one finalized.
Why it matters: Medicaid patients gain lower drug costs and access to Praluent at $225, while Regeneron secures a $27 billion investment pipeline, boosting US biotech jobs and pressuring other drugmakers to cut prices.
